Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Acute Effect of Resistance Exercise in Individuals With Hypertrophic Cardiomyopathy: A Pilot Study.

The American journal of cardiology·2026
Same author

Prevalence and Predictors of Cardiac Troponin Elevations Following Exercise: a Systematic Review, Meta-analysis, and Meta-regression.

European journal of preventive cardiology·2026
Same author

Sudden Cardiac Arrest in Athletes.

The New England journal of medicine·2026
Same author

Masters athletes with abnormal cardiovascular findings: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

European heart journal·2026
Same author

Masters Athletes With Abnormal Cardiovascular Findings: A Clinical Consensus Statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

Journal of the American College of Cardiology·2026
Same author

Syncope During Cycling.

JACC. Case reports·2026

Related Experiment Video

Updated: Jun 28, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Effectiveness of thrice weekly ezetimibe.

Carmelo V Venero1, Jose V Venero, Richard L Seip

  • 1Hartford Hospital, Hartford, Connecticut, USA.

The American Journal of Cardiology
|October 23, 2008
PubMed
Summary

Thrice-weekly ezetimibe effectively lowers cholesterol in patients intolerant to other medications. This dosing schedule significantly reduces total and LDL cholesterol while being well-tolerated.

Related Experiment Videos

Last Updated: Jun 28, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Ezetimibe, a cholesterol-lowering medication, typically has a daily dosing regimen.
  • Its long elimination half-life (22 hours) suggests potential for less frequent administration.
  • Patient intolerance to other lipid-lowering agents is a common clinical challenge.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of a thrice-weekly ezetimibe dosing regimen.
  • To assess lipid profile changes in patients receiving less frequent ezetimibe treatment.
  • To determine the viability of alternative ezetimibe dosing for specific patient populations.

Main Methods:

  • A study involving 33 patients treated with ezetimibe three times weekly for at least one month.
  • Collection of pre- and post-treatment lipid levels without concurrent changes in other lipid-lowering therapies.
  • Analysis of lipid changes, tolerability, and achievement of low-density lipoprotein cholesterol goals.

Main Results:

  • A significant reduction in total cholesterol by 15% (p <0.001) and low-density lipoprotein cholesterol by 20% (p <0.001).
  • Treatment duration averaged 58 days, with significant lipid reductions observed.
  • High tolerability (85% of patients) and achievement of low-density lipoprotein cholesterol goals in 48% of patients.

Conclusions:

  • Thrice-weekly ezetimibe administration is effective in reducing total and low-density lipoprotein cholesterol levels.
  • This dosing schedule is well-tolerated and represents a viable treatment option for patients with intolerance to other lipid-lowering medications.
  • Less frequent ezetimibe dosing can be a practical strategy for managing hyperlipidemia.